MedCity News February 9, 2024
Krish Ramadurai

The new era of full-stack compute-enabled bio companies will drive incredible advances in human health.

The first biotech revolution began 50 years ago when molecular biologists used DNA engineering to introduce a foreign genetic sequence into a bacteria and successfully produce a protein not encoded by the host genome. This revolutionary moment enabled a new era of scientific research that has radically advanced our understanding of how cells function in health and disease. It also opened the door to wholly new classes of therapies (recombinant proteins, monoclonal antibodies, targeted small molecules, gene and cell therapies, and gene editing) that have improved health outcomes for millions of patients.

Despite the transformative power of the first biotech revolution, traditional biopharmaceutical drug development...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Ascentage prices first biotech IPO of 2025, raising $126M
Medicare Reforms Necessitate More Formulary Oversight
Pharma Pulse 1/23/25: Technology’s Role in Trial Design Optimization, Trump's Impact on Medicare Drug Price Negotiations & more
GLP-1 drugs decrease incidence of 42 conditions – but there are risks
Cracking the code of drug delivery: Using computers and AI to make medicine work smarter

Share This Article